UAB Anti-Cancer Research Featured in Scientific AmericanAugust 25, 2008BIRMINGHAM, Ala. - Scientific American magazine focused on two University of Alabama at Birmingham (UAB) Comprehensive Cancer Center researchers in a news story on experimental next-generation anti-cancer therapies. David T. Curiel, M.D., Ph.D., is a UAB professor of medicine and director of the human gene therapy division, and Ronald Alvarez, M.D., is a UAB professor of medicine and director of the gynecologic oncology division. Both doctors are featured in a Scientific American special cancer edition, and both served as co-authors on the story "Tumor-busting viruses." The editors chose Curiel and Alvarez because of their research into a field call viral gene therapy, or virotherapy.
Virotherapy involves an experimental technique to target viruses to cancer cells while leaving healthy cells untouched. The viruses are genetically engineered to kill tumor cells in different ways. One way is by adopting the viruses' natural ability to invade and reproduce as a way to deliver target genes that make tumor cells more susceptible to existing chemotherapies. Curiel and Alvarez have been testing this concept with a virus compound called adenovirus in women with recurrent ovarian or other gynecological cancers. The clinical trial is still in the early stages, yet the compound has shown anti-tumor effects that appear safe to most patients, Curiel said. "We envision a substantial role for viruses - that is, therapeutic viruses - in 21st-century medicine," Curiel and Alvarez wrote in wrote in the story. First proposed in the 1940s, virotherapy now relies heavily on adenoviruses, a cause of the common cold that has been studied and altered extensively for medical research. Adenoviruses have the ability to shuttle targeted segments of DNA into a tumor cell and make biochemical changes that minimize damage to healthy cells. University of Alabama at Birmingham | |||||||||||||||||||||
|
Related Anti-Cancer Current Events and Anti-Cancer News Articles Iressa proves just as effective as chemotherapy for lung cancer Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center. Stopping germs from ganging up on humans Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson. A double-barreled immune cell approach for neuroblastoma Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online today in the journal Nature Medicine. Resveratrol prevents fat accumulation in livers of 'alcoholic' mice The accumulation of fat in the liver as a result of chronic alcohol consumption could be prevented by consuming resveratrol, according to a new study with mice. Pectin power Scientists have found a new possible explanation for why people who eat more fruit and vegetables may gain protection against the spread of cancers. Bisphenol A linked to chemotherapy resistance Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists. Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today. Discovering drugs, biofuels in tropical seas The National Institutes of Health has awarded $4 million to a group of Philippine and American scientists led by Oregon Health & Science University to aid in the discovery of new molecules and biofuels technology from marine mollusks for development in the Philippines. New way to make malaria medicine also first step in finding new antibiotics University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive. Is Bcl-2 protein a major obstacle in treating colorectal carcinoma? Apoptosis resistance has been shown to contribute to the development of different cancer entities, such as colorectal carcinoma (CRC). More Anti-Cancer Current Events and Anti-Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||